Aaron T Seaman1, Kristen L Seligman2, Khanh K Nguyen2,3, Zaid Al-Qurayshi2, Nicholas D Kendell2,4, Nitin A Pagedar2. 1. Department of Internal Medicine, University of Iowa, Iowa City, Iowa. 2. Department of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, Iowa. 3. Department of Otolaryngology, Loma Linda University, Loma Linda, California. 4. Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
BACKGROUND: Little is known about cancer survivors who discontinue survivorship care. The objective of this study was to characterize patients with head and neck cancer who discontinue survivorship care with their treating institution and identify factors associated with discontinuation. METHODS: This was a retrospective cohort study of patients diagnosed with head and neck cancer between January 1, 2014, and December 31, 2016, who received cancer-directed therapy at the University of Iowa Hospitals and Clinics (UIHC). Eligible patients achieved a cancer-free status after curative-intent treatment and made at least 1 visit 90+ days after treatment completion. The primary outcome was discontinuation of survivorship care, which was defined as a still living survivor who had not returned to a UIHC cancer clinic for twice the expected interval. Demographic and oncologic factors were examined to identify associations with discontinuation. RESULTS: Ninety-seven of the 426 eligible patients (22.8%) discontinued survivorship care at UIHC during the study period. The mean time in follow-up for those who discontinued treatment was 15.4 months. Factors associated with discontinuation of care included an unmarried status (P = .036), a longer driving distance to the facility (P = .0031), and a single-modality cancer treatment (P < .0001). Rurality was not associated with discontinuation (24.3% vs 21.6% for urban residence; P = .52), nor was age, gender, or payor status. CONCLUSIONS: The study results indicate that a sizeable percentage of head and neck cancer survivors discontinue care with their treating institution. Both demographic and oncologic factors were associated with discontinuation at the treating institution, and this points to potential clinical and care delivery interventions.
BACKGROUND: Little is known about cancer survivors who discontinue survivorship care. The objective of this study was to characterize patients with head and neck cancer who discontinue survivorship care with their treating institution and identify factors associated with discontinuation. METHODS: This was a retrospective cohort study of patients diagnosed with head and neck cancer between January 1, 2014, and December 31, 2016, who received cancer-directed therapy at the University of Iowa Hospitals and Clinics (UIHC). Eligible patients achieved a cancer-free status after curative-intent treatment and made at least 1 visit 90+ days after treatment completion. The primary outcome was discontinuation of survivorship care, which was defined as a still living survivor who had not returned to a UIHC cancer clinic for twice the expected interval. Demographic and oncologic factors were examined to identify associations with discontinuation. RESULTS: Ninety-seven of the 426 eligible patients (22.8%) discontinued survivorship care at UIHC during the study period. The mean time in follow-up for those who discontinued treatment was 15.4 months. Factors associated with discontinuation of care included an unmarried status (P = .036), a longer driving distance to the facility (P = .0031), and a single-modality cancer treatment (P < .0001). Rurality was not associated with discontinuation (24.3% vs 21.6% for urban residence; P = .52), nor was age, gender, or payor status. CONCLUSIONS: The study results indicate that a sizeable percentage of head and neck cancer survivors discontinue care with their treating institution. Both demographic and oncologic factors were associated with discontinuation at the treating institution, and this points to potential clinical and care delivery interventions.
Authors: Nitin A Pagedar; Nicholas Kendell; Alan J Christensen; Timothy A Thomsen; Michaela Gist; Aaron T Seaman Journal: Head Neck Date: 2020-05-23 Impact factor: 3.147
Authors: Katherine R Sterba; Jane Zapka; Kent E Armeson; Keisuke Shirai; Amy Buchanan; Terry A Day; Anthony J Alberg Journal: J Psychosoc Oncol Date: 2017-05-01
Authors: Julia R Van Liew; Alan J Christensen; M Bryant Howren; Lucy Hynds Karnell; Gerry F Funk Journal: Health Psychol Date: 2013-06-17 Impact factor: 4.267
Authors: Evan M Graboyes; Chanita Hughes Halbert; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Courtney H Marsh; Jessica McCay; Terry A Day; John M Kaczmar; Anand K Sharma; David M Neskey; Katherine R Sterba Journal: JCO Oncol Pract Date: 2020-08-27
Authors: Nosayaba Osazuwa-Peters; Matthew C Simpson; Longwen Zhao; Eric Adjei Boakye; Stephanie I Olomukoro; Teresa Deshields; Travis M Loux; Mark A Varvares; Mario Schootman Journal: Cancer Date: 2018-10-18 Impact factor: 6.860
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-03-01 Impact factor: 6.223
Authors: Catherine Chioreso; Xiang Gao; Irena Gribovskaja-Rupp; Chi Lin; Marcia M Ward; Mary C Schroeder; Charles F Lynch; Elizabeth A Chrischilles; Mary E Charlton Journal: Ann Surg Date: 2021-10-01 Impact factor: 13.787
Authors: Jenna L Adamowicz; Alan Christensen; M Bryant Howren; Aaron T Seaman; Nicholas D Kendell; Shylo Wardyn; Nitin A Pagedar Journal: J Rural Health Date: 2021-03-15 Impact factor: 5.667